Angelica Welsh | Authors

Articles

ADCs Stake Their Claim in Lymphoma Paradigm

September 28, 2018

Antibody–drug conjugate therapies are making a larger impact on the treatment paradigm for patients with lymphomas, especially following promising data for brentuximab vedotin and inotuzumab ozogamicin.